• Follow
  • Follow
  • Follow
  • About
    • About
    • Management Team
    • Board of Directors
  • Our Businesses
    • Active Ingredients (Ceapro)
    • Oral Thin Film (Nualtis)
  • Technologies
  • Investors and News
    • Press Releases
    • Events & Presentations
    • Investor Contacts
    • Stock Information
    • Financial Filings
      • SEC Filings
      • SEDAR
    • Governance
      • Corporate Governance
      • Board Committees
      • Board Diversity Matrix
      • Clawback Policy
      • Annual Reports
    • Email Alerts
  • Contact

Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer

by jtcir-auto | May 3, 2021 | Press Releases

– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncologyCHARLESTON, S.C., May 03, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)...

Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders

by jtcir-auto | Apr 28, 2021 | Press Releases

CHARLESTON, S.C., April 28, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests,...

Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results

by jtcir-auto | Mar 25, 2021 | Press Releases

– Company executing on growth strategy to build-out pipeline of development assets- Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q2 2021- Strong balance sheet enables significant optionality for growth...

Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results

by jtcir-auto | Mar 25, 2021 | Press Releases

– Company executing on growth strategy to build-out pipeline of development assets- Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q2 2021- Strong balance sheet enables significant optionality for growth...

Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement

by jtcir-auto | Mar 22, 2021 | Press Releases

CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests,...

Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement

by jtcir-auto | Mar 22, 2021 | Press Releases

CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests,...
« Older Entries
Next Entries »

Recent Posts

  • COSCIENS Biopharma Inc. Reports Q3 2026 Results and Provides Update On Convertible Debenture Offering
  • COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
  • COSCIENS ACQUIRES NUALTIS CORP.
  • COSCIENS Biopharma Inc. Reports Q2 2026 Results

Recent Comments

No comments to show.
Latest News:

Stock Info

TSX:

 

 

Sign Up For Alerts

Click Here and Stay Up To Date With Cosciens News and Events

 

Contact Us

© 2026 COSCIENS BIOPHARMA   All Rights Reserved   Terms and Conditions  Privacy Policy

  • Follow
  • Follow
  • Follow